During her time at CNET, Kim Wong-Shing loved demystifying the world of wellness to make it accessible to any reader. She was also passionate about exploring the intersections of health, history ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

A CGM helps me run marathons and do epic bike rides better than ever.

Abbott Laboratories and Decom will concentrate on competing in the huge market of potential continuous glucose monitor technology ... potential for Abbott's FreeStyle Libre CGM is a “mass ...

In our view, Abbott's FreeStyle Libre blood glucose monitor franchise is one of the most compelling innovations the firm has ever launched. Further, the pandemic provided a boon to the diagnostics ...

has seen a large boost to sales from strong demand for FreeStyle Libre - its continuous glucose monitor. Abbott had been facing supply issues for its Libre devices and said it will meet the demand ...

One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.